Regeneron Pharmaceuticals Inc. Common Stock (REGN)

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic mac…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

15,410

Website

www.regeneron.com/

Fundamentals

1-day range

$815.38$844.9

Market cap

$79.49B

P/E (trailing)

18.98

P/E (forward)

13.87

EPS (trailing)

$40.45

Dividend yield

0.46%

Beta

0.15

Avg. volume

952.1K

Ex-dividend date

August 18, 2026

Dividend pay date

August 31, 2026

Forecasts

27 analyst ratings

Regeneron Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• REGN

  Regeneron Pharmaceuticals Inc. Common Stock

  $793.96

  ▼ 1.70%
  Market cap $79.49BP/E 18.98
  $541$847
• SNY

  Sanofi ADS

  $44.82

  ▼ 0.04%
  Market cap $104.60BP/E 16.24
  $71.25$91.15
• TAK

  Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

  $18.04

  ▲ 0.06%
  Market cap $53.78BP/E —
  $4,102$6,033
• GSK

  GSK plc American Depositary Shares (Each representing two Ordinary Shares)

  $50.82

  ▲ 1.09%
  Market cap $105.65BP/E 15.53
  $1,441$2,282
• ONC

  BeOne Medicines Ltd. American Depositary Shares

  $366.79

  ▼ 1.53%
  Market cap $36.67BP/E 88.12
  $205.51$346
• VRTX

  Vertex Pharmaceuticals Incorporated Common Stock

  $541.72

  ▼ 1.06%
  Market cap $122.68BP/E 30.70
  $374.17$555.69
• ZTS

  Zoetis Inc. Class A Common Stock

  $77.36

  ▲ 3.12%
  Market cap $32.39BP/E 11.54
  $71$156.49

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication
  benzinga · 8/18/2026
• Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
  SeekingAlpha · 8/14/2026
• If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
  Benzinga · 8/14/2026
• Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
  Yahoo · 8/13/2026
• Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'
  Benzinga · 8/12/2026
• Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs
  Yahoo · 8/12/2026
• REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
  Yahoo · 8/11/2026
• American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review
  SeekingAlpha · 8/11/2026
• Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight
  Yahoo · 8/8/2026

• Arthur F. Ryan · July 2, 2026 · Sale

  200 @ $650.15
• Arthur F. Ryan · May 1, 2026 · Sale

  2 @ $710.87
• Arthur F. Ryan · May 1, 2026 · Sale

  1 @ $712.09
• Arthur F. Ryan · May 1, 2026 · Sale

  5 @ $701.76
• Arthur F. Ryan · May 1, 2026 · Sale

  6 @ $709.45
• Arthur F. Ryan · May 1, 2026 · Sale

  4 @ $707.4
• Arthur F. Ryan · May 1, 2026 · Sale

  7 @ $706.74
• Arthur F. Ryan · May 1, 2026 · Sale

  14 @ $705.56
• Arthur F. Ryan · May 1, 2026 · Sale

  15 @ $702.46
• Arthur F. Ryan · May 1, 2026 · Sale

  24 @ $703.46
• Arthur F. Ryan · April 1, 2026 · Sale

  40 @ $779.71
• Arthur F. Ryan · April 1, 2026 · Sale

  4 @ $778.24
• Arthur F. Ryan · April 1, 2026 · Sale

  9 @ $777.42
• Arthur F. Ryan · April 1, 2026 · Sale

  13 @ $776.62
• Arthur F. Ryan · April 1, 2026 · Sale

  14 @ $775.58

Institutional Ownership

March 31, 2026

Total shares held

83.07M

Total value held

$61.14B

Institutional holders

1377